NCT00101751已完成4 期
Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 4,877
- 试验地点
- 1
- 主要终点
- HbA1c and Incidence of hypoglycemia
研究概览
简要总结
This trial is conducted in the United States of America (USA). The purpose of this study is to compare the effectiveness and safety of a biphasic insulin aspart standard titration regimen when coupled with dietary intervention to standard titration without dietary intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes
排除标准
- 未提供
结局指标
主要结局
HbA1c and Incidence of hypoglycemia
时间窗: After 24 weeks of treatment
次要结局
- Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2DiabetesNCT00264901Novo Nordisk A/S5,652
已完成
1 期
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With ObesityMetabolism and Nutrition DisorderObesityNCT03095807Novo Nordisk A/S34
已完成
1 期
Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsMetabolism and Nutrition DisorderObesityNCT02300844Novo Nordisk A/S54
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy SubjectsHealthyDiabetesDiabetes Mellitus, Type 2NCT01473953Novo Nordisk A/S31
已完成
1 期
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightMetabolism and Nutrition DisorderObesityNCT02958085Novo Nordisk A/S96